Primary Malignant Melanoma of the Esophagus: A Case Report
Abstract
Primary Malignant Melanoma of the Esophagus (PMME) is an aggressive tumor with a median survival of about 13 months. Surgical extirpation is the only treatment for PMME. The most common clinical presentation is the onset of progressive dysphagia. Endoscopy presents a polypoid lesion occasionally in the middle and lower third of the esophagus. Definitive diagnoses are based on pathology and immunohistochemical examination with positive results for S-100, Human Melanoma Black (HMB)-45, and Melanoma-specific Antigen (Melan-A) proteins. We presented a 46-year-old man complaining of dysphagia and melena from the past two months. Gasteroesophagoscopy demonstrated a large polypoid in the lower third of the esophagus extending to the cardia. Histopathology of the biopsy specimen from the esophagus revealed positive staining for S-100, Human Melanoma Black (HMB)-45, and Melanoma-specific Antigen (Melan A) proteins that were all compatible with malignant melanoma of the esophagus. The patient underwent surgery followed by radiotherapy and Immunotherapy. The postoperative period was uneventful. No metastasis and recurrence was observed after more than 6 months of initial treatment. PMME is a rare but highly aggressive tumor. The diagnosis of PMME should be made by clinical symptoms, auxiliary examination, pathological examination, and immunohistochemistry markers. The problem of exact diagnosis at the early stages of the disease and effective treatment is still a challenge.
[2] Navarro-Ballester A, De Lazaro-De Molina S, Gaona-Morales J. Pri- mary malignant melanoma of the esophagus: A case report and re- view of the literature. The American Journal of Case Reports. 2015; 16:491-5. [DOI:10.12659/AJCR.894041] [PMID] [PMCID]
[3] Wang M, Chen J, Sun K, Zhuang Y, Xu F, Xu B, et al. Primary ma- lignant melanoma of the esophagus treated by endoscopic sub- mucosal dissection: A case report. Experimental and Therapeutic Medicine. 2016; 12(3):1319-22. [DOI:10.3892/etm.2016.3482] [PMID] [PMCID]
[4] Zheng J, Mo H, Ma S, Wang Z. Clinicopathological findings of prima- ry esophageal malignant melanoma: Report of six cases and review of the literature. International Journal of Clinical and Experimental Pathology. 2014; 7(10):7230-5. [PMID] [PMCID]
[5] Sabanathan S, Eng J, Pradhan GN. Primary malignant melanoma of the esophagus. American Journal of Gastroenterology. 1989; 84(12):1475-81. https://web.p.ebscohost.com/abstract?direct=tru e&profile=ehost&scope%3d16141851
[6] Chalkiadakis G, Wihlm JM, Morand G, Weill-Bousson M, Witz JP. Primary malignant melanoma of the esophagus. The Annals of Thoracic Surgery. 1985; 39(5):472-75. [DOI:10.1016/S0003- 4975(10)61963-7]
[7] Nonoshita T, Shioyama Y, Nomoto S, Ohga S, Ohnishi K, Atsumi K, et al. Effective palliative radiotherapy in primary malignant melano- ma of the esophagus: A case report. Cases Journal. 2009; 2(1):1-4. [DOI:10.4076/1757-1626-2-6928] [PMID] [PMCID]
[8] Sanchez AA, Wu TT, Prieto VG, Rashid A, Hamilton SR, Wang H. Comparison of primary and metastatic malignant melanoma of the esophagus: A clinicopathologic review of 10 cases. Archives of Pathology & Laboratory Medicine. 2008; 132(10):1623-9. [DOI:10.5858/2008-132-1623-COPAMM] [PMID]
[9] Fogarty G, Tartaglia C, Peters L. Primary melanoma of the esopha- gus well palliated by radiotherapy. The British Journal of Radiology. 2004; 77(924):1050-2. [DOI:10.1259/bjr/26921127] [PMID]
[10] Cheung MC, Perez EA, Molina MA, Jin X, Gutierrez JC, Franceschi D, et al. Defining the role of surgery for primary gastrointestinal tract melanoma. Journal of Gastrointestinal Surgery. 2008; 12(4):731-8. [DOI:10.1007/s11605-007-0417-3] [PMID]
[11] Langer R, Becker K, Feith M, Friess H, Höfler H, Keller G. Ge- netic aberrations in primary esophageal melanomas: Molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases. Modern Pathology. 2011; 24(4):495-501. [DOI:10.1038/mod- pathol.2010.220] [PMID]
Files | ||
Issue | Vol 6 No 5 (2021): September-October | |
Section | Case Report(s) | |
DOI | https://doi.org/10.18502/crcp.v6i5.8384 | |
Keywords | ||
Malignant melanoma Esophageal neoplasm Immunotherapy |
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |